Bill Me Later, and other MindTouch customers, see dramatic improvements in operational efficiency with collaboration, dashboards and dynamic reports across a plethora of Web services, enterprise applications, financial systems, databases, legacy systems, and intranets.
SAN DIEGO, November 3, 2008 – MindTouch, an open source software company and developers of MindTouch Deki, the most sophisticated wiki-based collaboration platform for enterprise collaboration and mashups, today announces new benchmarks in company growth in revenue, customers and partners as well as improvements in its flagship product, MindTouch Deki. Full Release
October 29th, 2008, San Diego, Calif. — Accumetrics, Inc. has appointed Timothy I. Still to the additional position of Chief Executive Officer. Mr. Still has been serving in the capacity of President and Chief Operating Officer for the company since earlier this year. Full Release
Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside
HCV Polymerase Inhibitor Being Presented at AASLD
SAN DIEGO, Nov. 1 — Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of HCV. These results are being presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in San Francisco, California, from October 31 - November 4. ANA598 is the Company’s investigational hepatitis C non- nucleoside polymerase inhibitor. Full Release
SAN DIEGO, Oct. 30 - Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has initiated dosing ANA773 in patients chronically infected with hepatitis C virus (HCV) in Part B of a two-part protocol designed to test ANA773 in both healthy volunteers and HCV patients. ANA773 is the Company’s investigational oral TLR7 agonist prodrug. In Part B of the study, patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort. Full Release
SAN DIEGO, Oct 28, 2008 - Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has initiated dosing ANA598 in patients chronically infected with hepatitis C virus (HCV) in a Phase Ib study. ANA598 is an investigational, oral, non-nucleoside polymerase inhibitor. The Phase Ib clinical trial is a double-blind, placebo-controlled study that will evaluate the tolerability, pharmacokinetics and viral kinetics of multiple, ascending doses of ANA598 over a period of three days. Anadys expects to enroll approximately 30 patients in the study of ANA598 at doses of 200 mg bid (twice-a-day), 400 mg bid and 800 mg bid. Full Release
Company Provides Update on Merger
CARLSBAD, Calif., Oct 28, 2008 — Invitrogen Corporation (NASDAQ: IVGN) today announced that its shareholders have voted to approve the company’s proposed merger with Applied Biosystems Inc. (NYSE: ABI) at a special meeting of shareholders held today. Full Release
World renowned fraud experts team with LifeLock® to shield consumers from identity theft
CARLSBAD, CA – October 29, 2008 – BasePoint Analytics®, a leading provider of scientific fraud
and risk analytic scoring solutions, today announced the availability of the BasePoint Identity Theft
Risk Assessment. The free analytic assessment, which takes just minutes to complete, is available
24/7 at www.basepointanalytics.com. Instant results include a personalized risk score, which
indicates a U.S. consumer’s risk of identity theft based on current behaviors and past experiences.
In addition to the risk score, consumers learn the top factors underlying their risk level, and a list of
key actions to take to better secure their identity. Full Release
Iomega Announces New Addition to Award-Winning Multimedia Drive Family: The ScreenPlay Pro HD Multimedia Drive
New Multimedia Drive Features Ethernet and Wireless Capability For Moving Content from the Home Network to the Home Theater
San Diego, October 29, 2008 - Iomega, an EMC company (NYSE: EMC) and a global leader in data protection, today added to its ScreenPlay™ series of Multimedia drives with the new Iomega® ScreenPlay™ Pro HD 1.0TB* Multimedia Drive. Full Release
Funding From NIAID of National Institutes of Health
San Diego, CA, October 22, 2008 – Trius Therapeutics, Inc. today announced the award of a $28 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, for the development of novel antibiotics directed against multiple Gram-negative bacterial pathogens. Under the five-year contract, Trius will develop novel drugs targeting bacterial DNA Gyrase and Topoisomerase IV, with the aim of optimizing these drugs for activity against relevant biodefense pathogens such as Yersinia pestis, Francisella tularensis, and Burkholderia pseudomallei. Trius will collaborate with investigators at Lawrence Livermore National Laboratories to identify and optimize lead molecules and to test these compounds for activity against Gram-negative biodefense pathogens. Full Release
Sept. 23 — Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Douglas B. Muchmore, MD, has joined the company as Vice President, Endocrinology Clinical Development. Full Release
